Olanzapine Modulate Lipid Metabolism and Adipose Tissue Accumulation via Hepatic Muscarinic M3 Receptor-Mediated Alk-Related Signaling

• Published in: Biomedicines 2024-06, Vol.12 (7), p.1403
• Main Authors: Su, Yueqing, Cao, Chenyun, Chen, Shiyan, Lian, Jiamei, Han, Mei, Liu, Xuemei, Deng, Chao
• Format: Article
• Language: English
• Subjects: Acetylcholine receptors (muscarinic); Adipose tissue; anaplastic lymphoma kinase; Antipsychotics; Body fat; Body mass index; Cevimeline; Cholesterol; Down-regulation; Drug metabolism; Dyslipidemia; Experiments; Fat metabolism; Females; Gene expression; Kinases; Ligands; Lipid metabolism; Lipids; Lipolysis; Liver; Metabolic disorders; muscarinic M3 receptors; Nervous system; Olanzapine; Protein-tyrosine kinase receptors; Proteins; Software; Up-regulation
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12071403

Olanzapine is an atypical antipsychotic drug and a potent muscarinic M3 receptor (M3R) antagonist. Olanzapine has been reported to cause metabolic disorders, including dyslipidemia. Anaplastic lymphoma kinase ( ), a tyrosine kinase receptor well known in the pathogenesis of cancer, has been recently identified as a key gene in the regulation of thinness via the regulation of adipose tissue lipolysis. This project aimed to investigate whether Olanzapine could modulate the hepatic pathway and lipid metabolism via M3R. Female rats were treated with Olanzapine and/or Cevimeline (an M3R agonist) for 9 weeks. Lipid metabolism and hepatic signaling were analyzed. Nine weeks' treatment of Olanzapine caused metabolic disturbance including increased body mass index (BMI), fat mass accumulation, and abnormal lipid metabolism. Olanzapine treatment also led to an upregulation of , , and its regulator , and a downregulation of , a transcriptional repressor of Alk in the liver. Moreover, there were positive correlations between Alk and , and , and a negative correlation between and . However, cotreatment with Cevimeline significantly reversed the lipid metabolic disturbance and adipose tissue accumulation, as well as the upregulation of the hepatic Alk signaling caused by Olanzapine. This study demonstrates evidence that Olanzapine may cause metabolic disturbance by modulating hepatic Alk signaling via M3R, which provides novel insight for modulating the hepatic signaling and potential interventions for targeting metabolic disorders.